기업명
파멥신
IR ROOM
등록일
2019-03-22
첨부파일
PDF 원문보기

궁금한 내용을 주주들과 공유해 보세요.   바로가기>>

로고

PharmAbcine Appoints Prof. Soohyeon Lee, MD/PhD to Its Scientific Advisory Board

 

DAEJEON, Republic of Korea, March 22, 2019 / PharmAbcine Inc. (KOSDAQ: 208340), a biopharmaceutical company focused on the development of next generation bio-therapeutics in medical unmet needs, announced today the appointment of Prof. Soohyeon Lee, MD/PhD., to its Scientific Advisory Board. Prof. Lee is a distinguished scientist and medical oncologist. She is well recognized for a number of scientific achievements and extensive experience with cancer patients and numerous global clinical trials in medical oncology at Yonsei University Medical Center, Pfizer and Celgene. After long experience as leading medical officer at global pharma companies, she recently joint to Korea University Medical Center to care patients.


"On behalf of the management team and Board, I am extremely pleased to welcome Prof. Lee to PharmAbcine. Prof. Lee's outstanding scientific expertise and experience in clinical oncology will be a tremendous asset as we continue to advance the development of novel immune oncology drug candidates including TTAC-0001, PMC-001, PMC-002R, PMC-201, PMC-402 and PMC-401s, PMC-122, PMC-305 and PMC-309. Additionally, we look forward to Dr. Lee's guidance in evaluating future product portfolio expansion opportunities, including TTAC-0001’s use in Keytruda combination therapies for various refractory cancers," said Dr. Jin-San Yoo, CEO and Chairman of PharmAbcine's Board of Directors.


Prof. Lee is currently a faculty member of department of medicinal oncology at Korea University School of Medicine. She received her MD and residency Yonsei University School of Medicine, and fellowship training at Samsung Medical Center and her PhD at Sungkyunkwan University College of Medicine.


"I am delighted to join PharmAbcine’s Scientific Advisory Board at such a critical time in the Company's clinical development," said Dr. Lee. "Based on the data generated to date and its profile, I believe TTAC-0001 and various assets has the potential to be effective against a wide range of solid tumor cancers. I look forward to working closely with PharmAbcine's management team and the Board to continue fostering the Company's future TTAC-0001 development, including the potential of combination therapies for oncology patients for no viable alternatives." 


About PharmAbcine, Inc.


PharmAbcine Inc. is a leading clinical stage biopharmaceutical company that develops fully human therapeutic antibody (mAb) and next generation multispecific antibody therapeutics based on in-house developed novel platform, DIG-Body, PIG-Body and TIG-Body using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.


PharmAbcine’s fully human antibody libraries and innovative selection system are our priceless proprietary assets. PharmAbcine provides antibody generation services by using antibody library and selection systems. PharmAbcine also provides co-development opportunities with novel antibodies.


Under the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has more than 300 patients derived cancer stem cell libraries and its animal model system for evaluating internal pipeline development.


Selected pipeline.


TTAC-0001(Tanibirumab): anti-KDR neutralizing fully human IgG with unique cross species cross reactivity has completed its Phase IIa recurrent GBM trial in Australia in August 2017. Promising molecule to combine with immune checkpoint blockade is open for out-licensing, co-development and combination clinical trials.


PMC-001(DIG-KT): next generation bispecific antibody neutralizing both VEGF-KDR and Angiopoietin-TIE2 pathways is superior to bevacizumab and Tanibirumab in preliminary studies. It also overcomes the Avastin® resistant brain tumor growth. Both PMC-002 and PMC-002R are different scaffolds neutralizing same targets like PMC-001.


PMC-201: next generation bispecific antibody neutralizing both VEGF-KDR and Notch-DLL4 pathways overcomes anti-cancer drug resistant tumor growth.


PMC-005BL: Anti-EGFRviii truly specific fully human IgG with internalization property is perfect for ADC, CAR-T and CAR-NK purpose and is open for co-development or out-licensing.


PMC-309a-z: anti-VISTA fully human antibodies collection as either agonistic or antagonistic. Antagonistic antibody performed synergy effects in combination with other immuno-oncology drug.


"3G-System" platform provides high performing production cell lines and we do have both


PMC-901: bevacizumab biosimilar cell line with 3g/L productivity.


PMC-902: aflibercept biosimilar cell line with > 3g/L productivity. 


For additional information about PharmAbcine is available through its website, http://www.pharmabcine.com


 

 

 

본 내용은 참고정보로, 최종 투자 판단의 책임은
본 게시물을 열람하는 이용자에게 있습니다.

※ 본 내용은 참고정보로, 최종 투자 판단의 책임은
본 게시물을 열람하는 이용자에게 있습니다.